Abstracts - Accepting Submissions
Abstracts must be submitted online via the abstract submission form in the conference web site. Emails and word processing files submitted outside of the Abstract Submission Site will not be accepted. Make sure your abstract complies with our abstract requirements and writing standards before submitting.
 
Abstracts Guidelines & Policies  
Requirements for Submission

• Prior Publication: An abstract is not eligible for submission if it has been presented at another national or international meeting or will be published prior to the Global Diabetes Alliance GDA Conference, October 26-29, 2010 .
• Sponsorship and Authorship Requirements: There is no limit to the number of abstracts an author may submit. However, an author of an abstract may appear as the lead author on only two (2) abstract submissions .

• Disclosure Information: You must disclose all relevant financial relationships with any commercial interest. This information is required of all authors for each submitted abstract. It is the responsibility of the Corresponding Author to ensure that the disclosure information of all co-authors is entered accurately into the Abstract Submission Site.
• Fees: There is a nonrefundable $35.00 (USD) submission fee for each abstract submitted. Expenses associated with the submission of the abstract are the responsibility of the Corresponding Author.

Character Count Specific Abstract Requirements

• Character Count: Abstracts are limited to 2000 characters. The character count does include spaces. Only the abstract title, body, tables and figures count towards the limit. Characters in the author and institution section are not counted. An abstract can have up to 2 attachments (tables and/or figures). Each figure counts as 300 characters. There is no automatic character deduction for tables. However, the character count of the table counts towards the 2000 character count limit.
• Abstract Body: Make abstracts as informative as possible, including a brief statement of the purpose of the study or why it was done, the methods used, the results observed, and conclusions based upon the results. Actual data should be summarized. It is inadequate to state "The results will be discussed" or "The data will be presented."

• Do NOT use subtitles (e.g., Methods, Results) in the abstract body.
• Do NOT include references, credits, or grant support information in the abstract.
• Do NOT enter author, title, or grant information into the “Abstract Body” text box.
• The use of standard abbreviations is requested. Examples include kg, g, mg, ml, L (liter), mEq (milliequivalent), m (meter), mmol/l (millimoles per liter), /(per), and % (percent).
• Place a special or unusual abbreviation in parentheses after the full word the first time it appears, then use the abbreviation throughout the remainder of the abstract.
• Use numerals to indicate numbers, except when beginning sentences.
• Nonproprietary (generic) names should be used the first time a drug is mentioned and typed in lowercase letters, followed by the trade name in parentheses. Trade names are always capitalized. Example: aspirin (Bufferin).
• When discussing therapeutic options, it is our preference that you use only generic names. If it is necessary to use a trade name, then those of several companies must be used. In addition, should your presentation include discussion of any unlabeled or investigational use of commercial product, you are required to disclose this at the time of presentation.